LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Kodu・Aktsiate loetelu・SCYNEXIS Inc

SCYNEXIS Inc

Suletud

0.56 -3.45

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

0.51

Max

0.63

Põhinäitajad
By Trading Economics
Sissetulek	-1.7M -8.6M
Müük	-1M 334K
Kasumimarginaal	-2,572.156
Töötajad	28
EBITDA	1.2M -8.4M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+503.45% upside

Turustatistika
By TradingEconomics
Turukapital	-1.6M 25M
Eelmine avamishind	4.01
Eelmine sulgemishind	0.56

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

0.9307 / 0.9907 Toetus ja vastupanu

SCYNEXIS Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. nov 2025, 18:59 UTC

Suurimad hinnamuutused turgudel

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17. nov 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17. nov 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17. nov 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17. nov 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17. nov 2025, 22:06 UTC

Omandamised, ülevõtmised, äriostud

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Rev $2.6B >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17. nov 2025, 22:02 UTC

Tulu

Trip.com Group 3Q EPS $4.02 >TCOM

17. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Adj EPS 26c >JHX

17. nov 2025, 21:40 UTC

Tulu

James Hardie Industries 2Q Loss/Shr 10c >JHX

17. nov 2025, 21:39 UTC

Tulu

James Hardie Industries 2Q Sales $1.29B >JHX

17. nov 2025, 21:38 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 21:38 UTC

Tulu

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q EPS BRL2.47 >XP

17. nov 2025, 21:10 UTC

Tulu

XP Inc. 3Q Rev BRL4.67B >XP

17. nov 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17. nov 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. nov 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17. nov 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17. nov 2025, 19:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 18:20 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17. nov 2025, 16:45 UTC

Omandamised, ülevõtmised, äriostud

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17. nov 2025, 16:16 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17. nov 2025, 16:15 UTC

Tulu

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17. nov 2025, 15:40 UTC

Omandamised, ülevõtmised, äriostud

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17. nov 2025, 15:22 UTC

Omandamised, ülevõtmised, äriostud

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17. nov 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Võrdlus sarnastega

Hinnamuutus

SCYNEXIS Inc Prognoos

Hinnasiht

By TipRanks

503.45% tõus

12 kuu keskmine prognoos

Keskmine 3.5 USD 503.45%

Kõrge 4 USD

Madal 3 USD

Põhineb 2 Wall Streeti analüütiku instrumendi SCYNEXIS Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

2 ratings

Osta

Hoia

Müü

Põhineb 2 analüütiku instrumendi SCYNEXIS Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9307 / 0.9907Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.